X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON LTD vs AUROBINDO PHARMA - Comparison Results

BIOCON LTD    Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON LTD AUROBINDO PHARMA BIOCON LTD/
AUROBINDO PHARMA
 
P/E (TTM) x 92.4 18.9 488.9% View Chart
P/BV x 7.8 4.8 164.6% View Chart
Dividend Yield % 0.1 0.3 45.1%  

Financials

 BIOCON LTD   AUROBINDO PHARMA
EQUITY SHARE DATA
    BIOCON LTD
Mar-18
AUROBINDO PHARMA
Mar-17
BIOCON LTD/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,188895 132.7%   
Low Rs305622 49.0%   
Sales per share (Unadj.) Rs68.7254.6 27.0%  
Earnings per share (Unadj.) Rs7.639.3 19.2%  
Cash flow per share (Unadj.) Rs14.046.6 30.0%  
Dividends per share (Unadj.) Rs1.002.50 40.0%  
Dividend yield (eoy) %0.10.3 40.6%  
Book value per share (Unadj.) Rs86.3160.0 54.0%  
Shares outstanding (eoy) m600.00585.88 102.4%   
Bonus/Rights/Conversions ISESOP-  
Price / Sales ratio x10.93.0 364.6%   
Avg P/E ratio x98.919.3 511.9%  
P/CF ratio (eoy) x53.416.3 328.1%  
Price / Book Value ratio x8.64.7 182.3%  
Dividend payout %13.26.4 208.0%   
Avg Mkt Cap Rs m447,900444,390 100.8%   
No. of employees `0006.114.0 44.0%   
Total wages/salary Rs m9,31117,678 52.7%   
Avg. sales/employee Rs Th6,705.810,667.8 62.9%   
Avg. wages/employee Rs Th1,514.21,264.3 119.8%   
Avg. net profit/employee Rs Th736.91,645.8 44.8%   
INCOME DATA
Net Sales Rs m41,234149,157 27.6%  
Other income Rs m2,0621,159 177.9%   
Total revenues Rs m43,296150,316 28.8%   
Gross profit Rs m8,29134,343 24.1%  
Depreciation Rs m3,8514,276 90.1%   
Interest Rs m615667 92.2%   
Profit before tax Rs m5,88730,558 19.3%   
Minority Interest Rs m21350 424.3%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5697,597 20.7%   
Profit after tax Rs m4,53123,012 19.7%  
Gross profit margin %20.123.0 87.3%  
Effective tax rate %26.724.9 107.2%   
Net profit margin %11.015.4 71.2%  
BALANCE SHEET DATA
Current assets Rs m41,48692,062 45.1%   
Current liabilities Rs m21,41366,223 32.3%   
Net working cap to sales %48.717.3 281.0%  
Current ratio x1.91.4 139.4%  
Inventory Days Days64106 60.4%  
Debtors Days Days9468 139.2%  
Net fixed assets Rs m50,66162,919 80.5%   
Share capital Rs m3,000586 512.0%   
"Free" reserves Rs m48,80893,133 52.4%   
Net worth Rs m51,80893,719 55.3%   
Long term debt Rs m17,8981,814 986.7%   
Total assets Rs m99,897162,494 61.5%  
Interest coverage x10.646.8 22.6%   
Debt to equity ratio x0.30 1,784.8%  
Sales to assets ratio x0.40.9 45.0%   
Return on assets %5.214.6 35.4%  
Return on equity %8.724.6 35.6%  
Return on capital %9.632.7 29.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m12,05875,838 15.9%   
Fx outflow Rs m7,34830,224 24.3%   
Net fx Rs m4,71045,613 10.3%   
CASH FLOW
From Operations Rs m6,62132,786 20.2%  
From Investments Rs m-6,840-17,870 38.3%  
From Financial Activity Rs m-2,397-19,153 12.5%  
Net Cashflow Rs m-2,612-4,239 61.6%  

Share Holding

Indian Promoters % 40.4 54.1 74.7%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 8.0 105.7%  
FIIs % 10.7 27.7 38.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 10.2 195.1%  
Shareholders   109,995 69,601 158.0%  
Pledged promoter(s) holding % 0.0 8.6 0.5%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON LTD With:   STERLING BIOTECH  PFIZER  ALKEM LABORATORIES  ORCHID PHARMA LTD  SANOFI INDIA  

Compare BIOCON LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 12.0% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, AUROBINDO PHARMA has posted a net profit of Rs 5 bn (down 12.0% YoY). Sales on the other hand came in at Rs 43 bn (up 15.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

BIOCON LTD Announces Quarterly Results (1QFY19); Net Profit Up 47.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, BIOCON LTD has posted a net profit of Rs 1 bn (up 47.2% YoY). Sales on the other hand came in at Rs 11 bn (up 20.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON LTD SHARE PRICE


Sep 21, 2018 (Close)

TRACK BIOCON LTD

  • Track your investment in BIOCON LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

BIOCON LTD - SANOFI INDIA COMPARISON

COMPARE BIOCON LTD WITH

MARKET STATS